Skip to Content

Lower-risk myelodysplastic syndromes treated with Reblozyl, luspatercept – Real-world outcomes

Sudipto Mukherjee from Cleveland Clinic in Ohio presents in this MEDtalk the results of a retrospective, observational cohort study of adults diagnosed with lower-risk myelodysplastic syndromes and treated with luspatercept.

Sudipto Mukherjee

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top